GTAEXS-617

Recursion has initiated the EXCELERIZE Phase 1 clinical trial of REC-3565, a selective MALT1 inhibitor designed to treat relapsed or refractory B-cell lymphomas.

Recursion Pharmaceuticals and Exscientia have completed a landmark $700 million merger, marking the largest AI-focused life sciences deal to date and combining complementary capabilities in biological and chemical AI platforms.

Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.

Recursion Pharmaceuticals' REC-617 Phase 1/2 study shows safety and efficacy in solid tumors, with one patient experiencing stable disease, signaling potential therapeutic benefits.

Recursion Pharmaceuticals presented Phase 1/2 data on REC-617, a CDK7 inhibitor, at an AACR Special Conference, showcasing its potential in treating advanced solid tumors.